Combining age, non-motor assessments, dopamine transporter (DAT) imaging, and CSF biomarkers effectively predicted Montreal Cognitive Assessment (MoCA) scores at the 2-year follow-up in newly diagnosed PD patients. The gene discussed is SLC6A3; the disease is Parkinson disease.